
EquitySector - HealthcareVery High Risk
Direct
NAV (27-Aug-26)
Returns (Since Inception)
Fund Size
₹112 Cr
Expense Ratio
0.86%
ISIN
INF663L01Z45
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+26.60%
+17.81% (Cat Avg.)
Since Inception
+14.68%
— (Cat Avg.)
| Equity | ₹106.58 Cr | 95.47% |
| Others | ₹5.06 Cr | 4.53% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹12.12 Cr | 10.86% |
| Divi's Laboratories Ltd | Equity | ₹11.55 Cr | 10.35% |
| Torrent Pharmaceuticals Ltd | Equity | ₹10.47 Cr | 9.38% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹6.94 Cr | 6.21% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹6.54 Cr | 5.86% |
| Ajanta Pharma Ltd | Equity | ₹5.81 Cr | 5.20% |
| Mankind Pharma Ltd | Equity | ₹5.2 Cr | 4.66% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹4.82 Cr | 4.32% |
| Dr. Lal PathLabs Ltd | Equity | ₹4.52 Cr | 4.05% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹4.2 Cr | 3.77% |
| Rubicon Research Ltd | Equity | ₹4.11 Cr | 3.68% |
| Abbott India Ltd | Equity | ₹3.61 Cr | 3.23% |
| Neuland Laboratories Ltd | Equity | ₹3.38 Cr | 3.03% |
| Navin Fluorine International Ltd | Equity | ₹3.14 Cr | 2.81% |
| Sai Life Sciences Ltd | Equity | ₹2.86 Cr | 2.56% |
| Cipla Ltd | Equity | ₹2.67 Cr | 2.39% |
| Pfizer Ltd | Equity | ₹2.52 Cr | 2.25% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹2.48 Cr | 2.23% |
| Anthem Biosciences Ltd | Equity | ₹2.22 Cr | 1.99% |
| Global Health Ltd | Equity | ₹2.05 Cr | 1.83% |
| Zydus Lifesciences Ltd | Equity | ₹1.5 Cr | 1.35% |
| Fortis Healthcare Ltd | Equity | ₹1.43 Cr | 1.28% |
| Lupin Ltd | Equity | ₹1.37 Cr | 1.23% |
| Manipal Health Enterprises Ltd | Equity | ₹1.08 Cr | 0.96% |
| Orchid Pharma Ltd | Equity | ₹1.01 Cr | 0.91% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹1 Cr | 0.90% |
| ICICI Lombard General Insurance Co Ltd | Equity | ₹0.99 Cr | 0.89% |
| Lenskart Solutions Ltd | Equity | ₹0.76 Cr | 0.68% |
| Sagility Ltd | Equity | ₹0.53 Cr | 0.48% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.5 Cr | 0.45% |
| Net Receivables / (Payables) | Cash | ₹0.23 Cr | 0.21% |
Large Cap Stocks
32.97%
Mid Cap Stocks
32.59%
Small Cap Stocks
28.94%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹102.45 Cr | 91.76% |
| Basic Materials | ₹3.14 Cr | 2.81% |
| Financial Services | ₹0.99 Cr | 0.89% |
Standard Deviation
This fund
--
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.90
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.55
Higher the better
Since January 2025
Since January 2025
Since January 2025
Since January 2025
ISIN INF663L01Z45 | Expense Ratio 0.86% | Exit Load No Charges | Fund Size ₹112 Cr | Age 1 year 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹26,949 Cr
Address
Nirlon House, 2nd Floor, Mumbai, 400 030
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments